Physician profile
Dana A Johnson
NPI 1073512133
$6,525.13
in general payments reported to CMS, 2019-2025
45 companies · $1,655 in 2025
The $1,655 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $901 · 2020: $79.36 · 2021: $312 · 2022: $919 · 2023: $470 · 2024: $2,188 · 2025: $1,655.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,120 · Education: $193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,120.18 |
| Education | $192.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $686.53 | 2019-2025 | Tecvayli, Darzalex, Talvey |
| Novartis Pharmaceuticals Corporation | $638.11 | 2019-2025 | |
| Amgen INC. | $450.52 | 2019-2024 | Nplate, Vectibix, Lumakras |
| Merck Sharp & Dohme LLC | $335.56 | 2019-2025 | Keytruda, Welireg |
| Pfizer INC. | $318.73 | 2019-2025 | |
| Genmab U.S., INC. | $304.03 | 2023-2025 | Tivdak, Epkinly |
| Regeneron Healthcare Solutions, INC. | $295.80 | 2019-2025 | Libtayo |
| Astrazeneca Pharmaceuticals LP | $282.97 | 2019-2025 | Tagrisso, Enhertu |
| Genentech USA, INC. | $252.10 | 2019-2025 | Tecentriq, Venclexta, Alecensa |
| Daiichi Sankyo INC. | $240.18 | 2019-2025 | Enhertu, Injectafer, Datroway |
| Celgene Corporation | $220.44 | 2019-2025 | Reblozyl, Opdivo, Opdualag |
| Seagen INC. | $204.72 | 2022-2024 | Adcetris |
| Array Biopharma INC | $202.10 | 2021-2025 | Xalkori, Braftovi, Lorbrena |
| Lilly USA, LLC | $200.45 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Astellas Pharma US INC | $190.38 | 2023-2025 | Xtandi, Padcev, Vyloy |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dana Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.